1. Home
  2. PRAX vs CPB Comparison

PRAX vs CPB Comparison

Compare PRAX & CPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

HOLD

Current Price

$263.71

Market Cap

7.1B

Sector

Health Care

ML Signal

HOLD

Logo Campbell Soup Company

CPB

Campbell Soup Company

HOLD

Current Price

$22.79

Market Cap

6.5B

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRAX
CPB
Founded
2015
1869
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Packaged Foods
Sector
Health Care
Consumer Staples
Exchange
Nasdaq
Nasdaq
Market Cap
7.1B
6.5B
IPO Year
2020
1994

Fundamental Metrics

Financial Performance
Metric
PRAX
CPB
Price
$263.71
$22.79
Analyst Decision
Strong Buy
Hold
Analyst Count
15
18
Target Price
$572.13
$26.06
AVG Volume (30 Days)
427.5K
8.7M
Earning Date
05-08-2026
06-01-2026
Dividend Yield
N/A
7.63%
EPS Growth
N/A
6.35
EPS
N/A
1.55
Revenue
N/A
$10,253,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$7,758.26
$0.11
P/E Ratio
N/A
$14.81
Revenue Growth
N/A
6.40
52 Week Low
$37.25
$19.56
52 Week High
$366.52
$34.18

Technical Indicators

Market Signals
Indicator
PRAX
CPB
Relative Strength Index (RSI) 39.24 69.68
Support Level $157.29 $19.78
Resistance Level $342.62 $31.86
Average True Range (ATR) 21.68 0.74
MACD -6.71 0.26
Stochastic Oscillator 20.77 84.59

Price Performance

Historical Comparison
PRAX
CPB

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

About CPB Campbell Soup Company

Over the past 150-plus years, Campbell's has evolved into a leading domestic packaged food manufacturer, with a portfolio that extends beyond its iconic red-and-white labeled canned soup. In fiscal 2025 (July year-end), snacks accounted for 43% of its revenue, followed by soup (27%), other simple meals (23%), and beverages (7%). Beyond its namesake, its brands include Pepperidge Farm, Goldfish, Snyder's of Hanover, Swanson, Pacific Foods, Prego, Pace, V8, and, most recently, Rao's (a deal that closed in 2024). Around 90% of its revenue results from the US and the remainder from Canada and Latin America.

Share on Social Networks: